Skip to main content

Table 3 Rate of Incident TB in entire cohort and subgroup analysis

From: Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India

Characteristics Entire Cohort
(n = 1904)
Patients with NO baseline prevalent TB
(n = 1267)
Number of patients (n) Incidence rate (95% CI)per 100 person years Number of patients (n) Incidence rate (95% CI)
per 100 person years
Total patients 182 1.85 (1.604, 2.144) 113 1.73 (1.436, 2.076)
Age (years)
  ≤ 40 years 100 1.83 (1.502, 2.223) 63 1.75 (1.363, 2.233)
  > 40 years 82 1.89 (1.521, 2.344) 50 1.71 (1.292, 2.249)
Gender
 Female 50 1.49 (1.132, 1.971) 35 1.34 (0.961, 1.865)
 Male 132 2.04 (1.721, 2.421) 78 1.98 (1.589, 2.478)
History of prior TB at baseline
 Yes 69 2.11 (1.666, 2.671)   
 No 113 1.73 (1.436, 2.076)   
Haemoglobin at baseline (g/dl) (n = 156)   (n = 88)  
  ≤ 10 53 2.84 (2.171, 3.719) 65 2.79 (1.853, 4.196)
  > 10 103 1.58 (1.304, 1.919) 23 1.43 (1.125, 1.830)
Virologic status on ART
 Virologic failure (VF) 105 8.51 (7.030, 10.307) 71 10.23 (8.107, 12.910)
 Virologic suppression (VS) 77 0.90 (0.717, 1.122) 42 0.72 (0.530, 0.972)
IPT
 ART plus IPT 5 0.20 (0.081, 0.469) 2 0.11 (0.026, 0.423)
 ART alone 177 2.44 (2.106, 2.828) 111 2.38 (1.979, 2.872)
Duration of ART (months)
  ≤ 12 33 24.32 (17.293, 34.215) 23 25.58 (16.998, 38.492)
 13–36 52 5.46 (4.162, 7.167) 29 4.32 (3.005, 6.223)
 37–60 44 2.54 (1.890, 3.413) 28 2.41 (1.666, 3.495)
  > 60 53 0.75 (0.579, 0.992) 33 0.72 (0.507, 1.004)
Pre ART CD4 count (cells/mm3)
  ≤ 50 32 2.28 (1.612, 3.224) 18 2.57 (1.621, 4.085)
 51–200 108 2.20 (1.824, 2.660) 59 1.98 (1.537, 2.560)
 201–500 41 1.28 (0.943, 1.740) 35 1.35 (0.967, 1.875)
  >  500 1 0.32 (0.045, 2.303) 1 0.36 (0.052, 2.625)
Current/ updated CD4 count (cells/mm3)
  ≤ 200 107 7.36 (6.090, 8.896) 65 8.35 (6.548, 10.648)
 201–350 36 1.75 (1.265, 2.432) 22 1.64 (1.078, 2.486)
 351–500 20 1.03 (0.667, 1.602) 12 0.97 (0.552, 1.711)
  >  500 19 0.43 (0.277, 0.681) 14 0.44 (0.260, 0.741)
  1. ART antiretroviral therapy, IPT Isoniazid preventive therapy, TB tuberculosis